Celularity presented new data on their placenta-derived NK cell therapy program.

The therapy shows potential as senolytic agents to target and eliminate senescent cells.

CEO Dr. Robert Hariri highlights the natural effectiveness of NK cells in clearing out damaged cells.

The company leverages the biological properties of the placenta for various age-related diseases.

NK cells could potentially change aging biology by clearing out senescent cells and introducing new cells.

Celularity is seeking collaborative partners to advance their work in cellular senescence and age-related degenerative changes.

The company aims to revolutionize aging biology through their innovative approach.